Corey J. Langer

Overview

Best Publications

• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  Joan H. Schiller;David Harrington;Chandra P. Belani;Corey Langer

  6389
  Citations

• CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

  Andy Trotti;A.Dimitrios Colevas;Ann Setser;Valerie Rusch

  3098
  Citations

• Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

  Walter J. Curran;Rebecca Paulus;Corey J. Langer;Ritsuko Komaki

  1472
  Citations

• Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

  Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  1443
  Citations

• Non–Small Cell Lung Cancer

  David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang

  1193
  Citations

• Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival

  Henry T. Hoffman;Kimberly Porter;Lucy H. Karnell;Jay S. Cooper

  870
  Citations

• Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

  Nasser Hanna;Paul A. Bunn;Corey Langer;Lawrence Einhorn

  801
  Citations

• Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

  Corey J. Langer;Judith Manola;Patricia Bernardo;John W. Kugler

  705
  Citations

• Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

  Primo N. Lara;Ronald Natale;John Crowley;Heinz Josef Lenz

  615
  Citations

• Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

  Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  611
  Citations

• National Cancer Database report on cancer of the head and neck: 10-year update

  Jay S. Cooper;Kim Porter;Katherine Mallin;Henry T. Hoffman

  486
  Citations

• Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

  Suresh S. Ramalingam;Suzanne E. Dahlberg;Corey J. Langer;Robert Gray

  472
  Citations

• Current management of brain metastases, with a focus on systemic options

  Corey J. Langer;Minesh P. Mehta

  463
  Citations

• Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

  Stephen J. Bagley;Shawn Kothari;Charu Aggarwal;Joshua M. Bauml

  459
  Citations

• Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410

  W Curran;C Scott;C Langer;R Komaki

  451
  Citations

• Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911

  Corey J. Langer;Jonathan Harris;Eric M. Horwitz;Nicos Nicolaou

  437
  Citations

• Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

  Charu Aggarwal;Jeffrey C. Thompson;Taylor A. Black;Sharyn I. Katz

  422
  Citations

• Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

  Daniel D. Karp;Luis G. Paz-Ares;Silvia Novello;Paul Haluska

  369
  Citations

• The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

  Corey J. Langer;Benjamin Besse;Antonio Gualberto;Elizabeth Brambilla

  361
  Citations

• Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

  Scott N Gettinger;Lyudmila A Bazhenova;Corey J Langer;Ravi Salgia

  354
  Citations